MYGN Myriad Genetics, Inc. Stock Quote

MYGN [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-2.87	Insider Own	2.50%	Shs Outstand	74.70M	Perf Week	10.46%
Market Cap	1.98B	Forward P/E	485.64	EPS next Y	0.06	Insider Trans	0.02%	Shs Float	73.38M	Perf Month	49.64%
Income	-214.10M	PEG	-	EPS next Q	-0.13	Inst Own	-	Short Float	13.18%	Perf Quarter	114.45%
Sales	597.50M	P/S	3.32	EPS this Y	-250.00%	Inst Trans	0.10%	Short Ratio	12.52	Perf Half Y	122.58%
Book/sh	12.17	P/B	2.19	EPS next Y	150.00%	ROA	-13.20%	Target Price	17.38	Perf Year	-7.64%
Cash/sh	2.16	P/C	12.37	EPS next 5Y	8.10%	ROE	-20.10%	52W Range	9.24 - 30.13	Perf YTD	35.07%
Dividend	-	P/FCF	-	EPS past 5Y	-35.10%	ROI	-18.20%	52W High	-11.35%	Beta	1.73
Dividend %	-	Quick Ratio	2.80	Sales past 5Y	-2.50%	Gross Margin	69.80%	52W Low	189.07%	ATR	1.38
Employees	2700	Current Ratio	3.00	Sales Q/Q	-22.10%	Oper. Margin	-41.90%	RSI (14)	82.68	Volatility	7.53% 6.23%
Optionable	Yes	Debt/Eq	0.25	EPS Q/Q	-68.60%	Profit Margin	-32.50%	Rel Volume	1.04	Prev Close	25.80
Shortable	Yes	LT Debt/Eq	0.25	Earnings	Nov 09 AMC	Payout	-	Avg Volume	772.67K	Price	26.71
Recom	3.10	SMA20	27.79%	SMA50	42.08%	SMA200	80.99%	Volume	801,535	Change	3.53%

Sep-26-19

Downgrade

BofA/Merrill

Neutral → Underperform

$30 → $28

Aug-14-19

Downgrade

Piper Jaffray

Overweight → Neutral

$45 → $40

Aug-02-19

Upgrade

BofA/Merrill

Underperform → Neutral

Aug-01-19

Upgrade

Barclays

Underweight → Equal Weight

$18 → $40

Jul-29-19

Downgrade

Needham

Strong Buy → Hold

Jul-09-19

Downgrade

Cowen

Outperform → Market Perform

Mar-12-19

Reiterated

Needham

Strong Buy

$37 → $41

Jan-03-19

Initiated

Needham

Strong Buy

$36

Nov-30-18

Upgrade

Goldman

Sell → Neutral

Oct-10-18

Upgrade

Piper Jaffray

Neutral → Overweight

Jul-11-18

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Mar-21-18

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Jan-29-18

Initiated

Goldman

Sell

$32

Jan-22-18

Reiterated

Barclays

Equal Weight

$30 → $35

Jan-05-18

Initiated

BTIG Research

Buy

$41

Oct-02-17

Resumed

Leerink Partners

Mkt Perform

$31

Aug-09-17

Reiterated

Barclays

Equal Weight

$28 → $26

Feb-08-17

Upgrade

Ladenburg Thalmann

Sell → Neutral

Jan-18-17

Initiated

Deutsche Bank

Sell

$15

Oct-10-16

Downgrade

Ladenburg Thalmann

Neutral → Sell

Jan-12-21 08:40AM	Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm Zacks
Jan-11-21 02:05PM	Myriad Genetics Forms Strategic Partnership with Illumina in Oncology GlobeNewswire +5.21%
Jan-08-21 07:05AM	Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula® GlobeNewswire
Jan-06-21 10:20AM	Myriad Genetics Up on Strategic-Options Plan for Autoimmune Unit TheStreet.com +6.58%
Jan-05-21 04:05PM	Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International Operations GlobeNewswire +8.33%
Jan-04-21 07:05AM	Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-20 07:05AM	New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations GlobeNewswire
Dec-09-20 11:30AM	Why Is Myriad (MYGN) Up 8.3% Since Last Earnings Report? Zacks
Nov-30-20 11:00AM	IPM Launches Innovative Program for Rheumatoid Arthritis PR Newswire
Nov-17-20 07:05AM	Suffering in Silence: Two-Thirds of Older Adults Say They Wont Treat Their Depression GlobeNewswire
Nov-16-20 07:05AM	Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China GlobeNewswire
Nov-15-20 08:00PM	Burning Rock Announces In-Licensing of Myriad myChoice® Tumor Testing in China GlobeNewswire
Nov-11-20 07:05AM	New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis GlobeNewswire
Nov-10-20 08:25AM	Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates Zacks
Nov-09-20 09:30PM	Myriad Genetics Inc (MYGN) Q1 2021 Earnings Call Transcript Motley Fool +18.96%
03:15PM	Myriad Genetics, Inc. to Host Earnings Call ACCESSWIRE
09:45AM	Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:00AM	Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter GlobeNewswire
Nov-04-20 07:05AM	Myriad Genetics to Announce Quarterly Financial Results on November 9, 2020 GlobeNewswire +5.71%
Oct-26-20 12:31PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-16-20 09:05AM	German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test GlobeNewswire
Oct-15-20 07:05AM	Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests GlobeNewswire
Oct-05-20 12:11PM	Here is What Hedge Funds Think About Myriad Genetics, Inc. (MYGN) Insider Monkey
Sep-16-20 10:58AM	Insider Sells Myriad Genetics Stock Benzinga
Sep-12-20 11:30AM	Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-10-20 07:05AM	Myriad Genetics Expands Board of Directors with New Member GlobeNewswire
Sep-03-20 06:21PM	Analyst Report: Myriad Genetics, Inc. Morningstar Research -7.42%
Aug-24-20 11:04AM	ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer Zacks
Aug-21-20 07:05AM	American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer GlobeNewswire
Aug-14-20 04:05PM	Myriad Genetics Announces Inducement Awards GlobeNewswire -5.38%
10:46AM	Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated Zacks
06:36AM	COVID-19 Pandemic Wreaks Havoc on Myriad Genetics' Fiscal Q4 Results Motley Fool
12:30AM	Myriad Genetics Inc (MYGN) Q4 2020 Earnings Call Transcript Motley Fool
Aug-13-20 06:15PM	Myriad Genetics (MYGN) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:19PM	Recap: Myriad Genetics Q4 Earnings Benzinga
04:08PM	Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors GlobeNewswire
04:07PM	Myriad Genetics Reports Fiscal Fourth-Quarter 2020 Financial Results GlobeNewswire
Aug-12-20 11:01AM	Preview: Myriad Genetics's Earnings Benzinga +5.15%
Aug-10-20 07:05AM	New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions GlobeNewswire
Aug-06-20 07:05AM	Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020 GlobeNewswire
Aug-04-20 12:30PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-31-20 07:05AM	Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer GlobeNewswire
Jul-29-20 07:05AM	Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test GlobeNewswire
Jul-28-20 07:05AM	Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra® GlobeNewswire
Jul-22-20 07:05AM	Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. GlobeNewswire
Jul-07-20 06:32PM	Myriad Genetics, OptraHEALTH Partner to Offer Cancer Knowledge Zacks
07:05AM	Myriad Announces New Studies Validating the Ability of Myriads riskScore® Test to Modify Breast Cancer Risk Prediction GlobeNewswire
Jul-06-20 10:04AM	Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis Zacks
07:05AM	Myriad Announces Partnership with OptraHEALTH® to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients GlobeNewswire
Jul-05-20 08:56PM	Hedge Funds Never Been Less Bullish On Myriad Genetics, Inc. (MYGN) Insider Monkey
Jul-02-20 08:46AM	Myriad Genetics Unveils New Home DNA Sample Collection Kit Zacks
Jul-01-20 07:05AM	Myriad Launches New GeneSight® Psychotropic Patient Collection Kit GlobeNewswire
Jun-29-20 11:27AM	Myriad Genetics' myPath Melanoma Proved Superior Per New Study Zacks
Jun-25-20 07:05AM	New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment GlobeNewswire
Jun-23-20 11:19AM	Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger Zacks
Jun-22-20 10:32AM	4 Toxic Stocks to Disown or Play Short to Book Profits Zacks
Jun-17-20 11:53AM	Myriad Genetics' Prolaris Receives Favorable Coverage Policies Zacks
Jun-15-20 07:05AM	Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider GlobeNewswire +5.83%
Jun-12-20 07:48PM	Edited Transcript of MYGN earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-11-20 02:22PM	Here's Why Myriad Genetics Is Tumbling Today Motley Fool -20.92%
11:24AM	Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries GlobeNewswire
Jun-09-20 10:23AM	Myriad Genetics' Test Better Predicts Drug Levels Per Study Zacks
Jun-08-20 07:05AM	New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing GlobeNewswire
Jun-05-20 09:00AM	Keep These 4 Toxic Stocks Off Your Portfolio to Avoid Losses Zacks
Jun-04-20 11:31AM	Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report? Zacks
07:05AM	Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer GlobeNewswire
May-29-20 07:05AM	Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients GlobeNewswire
May-28-20 07:05AM	Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D. GlobeNewswire
May-27-20 11:14AM	Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories Zacks
May-26-20 09:27AM	Dump These 4 Toxic Stocks or Sell Short for Timely Profits Zacks
07:00AM	Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study GlobeNewswire
May-20-20 08:12AM	The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test Benzinga
07:05AM	Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer GlobeNewswire
May-18-20 11:55AM	Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem Zacks
May-13-20 05:26PM	Biotech ETFs to Gain From Latest Advancements in Cancer Drugs Zacks
May-11-20 07:05AM	Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza (olaparib) In Patients with Advanced Ovarian Cancer GlobeNewswire +8.89%
May-06-20 11:49AM	Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View Zacks
May-05-20 11:01PM	Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript Motley Fool
04:05PM	Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results GlobeNewswire
Apr-28-20 04:05PM	Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 GlobeNewswire
12:33PM	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-20-20 07:05AM	Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder GlobeNewswire
Apr-08-20 07:05AM	Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic GlobeNewswire
Apr-07-20 11:35AM	Hedge Funds Are Buying Myriad Genetics, Inc. (MYGN) Insider Monkey
09:32AM	Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement Zacks
Apr-06-20 07:05AM	Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC GlobeNewswire +25.16%
Mar-30-20 07:05AM	Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer GlobeNewswire
Mar-23-20 07:13AM	A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN) Simply Wall St.
07:05AM	Myriad Announces Board of Directors Leadership Transition GlobeNewswire
Mar-19-20 09:46AM	Myriad Grows Internationally, Hereditary Cancer Revenues Soft Zacks +24.13%
Mar-18-20 07:05AM	NCCN Updates Professional Guidelines Recommending Biomarker Testing for Unfavorable Intermediate and High-Risk Patients with Prostate Cancer GlobeNewswire -5.42%
Mar-07-20 11:31AM	Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-04-20 08:29AM	Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems Zacks +5.74%
Mar-03-20 09:28AM	Dump These 5 Toxic Stocks Right Away Zacks -7.42%
Feb-28-20 06:58AM	The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher Zacks
Feb-17-20 04:02PM	Edited Transcript of MYGN earnings conference call or presentation 6-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
09:31AM	Steer Clear Of These 5 Toxic Stocks Before It's Too Late Zacks
07:46AM	Myriad Genetics (MYGN) Releases Favorable Prolaris Results Zacks
Feb-14-20 07:05AM	New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy GlobeNewswire
Feb-13-20 10:36AM	Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA Zacks

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parkinson Paul	EVP Strategy and Innovation	Jan 08	Sale	25.00	11,824	295,600	76,746	Jan 11 04:40 PM
Phanstiel S. Louise	Director	Nov 11	Buy	16.62	15,000	249,336	66,790	Nov 12 08:57 AM
Ford Alexander	Chief Operating Officer	Sep 15	Sale	13.78	2,804	38,630	151,159	Sep 16 09:56 AM
Lambert Nicole	President, MGL	Feb 12	Sale	19.73	4,354	85,915	59,150	Feb 12 06:28 PM
Ford Alexander	President, MWH	Feb 05	Sale	30.00	7,273	218,190	142,438	Feb 07 02:39 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience